The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Amazon Few companies enjoy as strong of a competitive moat as Amazon (NASDAQ: AMZN). Actually, Amazon has multiple strong moats. There's a networking moat with the company's e-commerce platform ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Jan. 1, 2025 — Researchers have traced a cellular route Ebola virus (EBOV) uses to traverse the inner and outer layers of skin and emerge onto the skin's surface. The study identifies new cell ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...